Drug pricing

News

BMS says it will set Cobenfy's UK price the same as the US

Bristol Myers Squibb's price tag for schizophrenia drug Cobenfy in the UK is a manifestation of Trump's most favoured nation drug pricing policy.

Market Access

pharmaphorum podcast Episode 141, Alice Valder Curran

Policy in focus: Trump’s Most Favoured Nations drug pricing ...

Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.

News

AbbVie loses bid to block 340B law in Mississippi

Battle lines are being drawn on 340B rebates as AbbVie loses a bid to block a Mississippi law seeking to retain discounts for contract pharmacies.

News

AZ halts UK investment, and Lilly, Sanofi follow suit

After MSD's bombshell retreat from a big UK investment plan, AstraZeneca, Lilly, and Sanofi are also pressing pause on new projects.

News

Reaction to MSD's UK exit as government tries to renew talks

The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.

News

Pharma says UK is 'tumbling down' rankings for investment

The UK is losing out to competitors in attracting investment in R&D, clinical trials, and capital projects, says a report from the ABPI pharma group.

BMS says it will set Cobenfy's UK price the same as the US

Policy in focus: Trump’s Most Favoured Nations drug pricing ...

AbbVie loses bid to block 340B law in Mississippi

AZ halts UK investment, and Lilly, Sanofi follow suit

Reaction to MSD's UK exit as government tries to renew talks

Pharma says UK is 'tumbling down' rankings for investment

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Drug pricing

Editor's Picks